LYNCH DANIEL 4
4 · SpringWorks Therapeutics, Inc. · Filed Feb 24, 2025
Insider Transaction Report
Form 4
LYNCH DANIEL
Director
Transactions
- Sale
Common Stock
2025-02-20$60.14/sh−44,018$2,647,185→ 86,526 total - Sale
Common Stock
2025-02-20$61.24/sh−3,582$219,349→ 82,944 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on May 3, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.16 to $61.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.